Arrowhead Pharmaceuticals Inc (ARWR)

Oct 01, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance

Oct 01, 2026

Oct 01, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) stock price, news, quote and history - uk.finance.yahoo.com

Oct 01, 2026

Sep 30, 2026

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits

Sep 30, 2026

Sep 30, 2026

Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast - GlobeNewswire Inc.

Sep 30, 2026

Sep 30, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance Australia

Sep 30, 2026

Sep 30, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 30, 2026

Sep 29, 2026

Long term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1 - TradingView

Sep 29, 2026

Sep 29, 2026

ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView

Sep 29, 2026

Sep 29, 2026

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Arrowhead Pharmaceuticals, Inc.

Sep 29, 2026

Sep 26, 2026

ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits

Sep 26, 2026

Sep 24, 2026

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - Yahoo Finance

Sep 24, 2026

Sep 24, 2026

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating - Investing.com

Sep 24, 2026

Sep 24, 2026

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating By Investing.com - Investing.com South Africa

Sep 24, 2026

Sep 23, 2026

Arrowhead Pharmaceuticals Slides as Investors Reassess Recent ARO-DIMER-PA Data - Quiver Quantitative

Sep 23, 2026

Sep 23, 2026

Arrowhead Pharmaceuticals Drops 5.4% Amid Sector-Wide Selling - AlphaStreet

Sep 23, 2026

Sep 22, 2026

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Unpacking A 59.91% Upside Potential - DirectorsTalk Interviews

Sep 22, 2026

Sep 19, 2026

Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds - Yahoo Finance

Sep 19, 2026

Sep 18, 2026

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress - TradingView

Sep 18, 2026

Sep 18, 2026

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands - finance.yahoo.com

Sep 18, 2026

Sep 18, 2026

Arrowhead Pharmaceuticals Inc. (ARWR) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 18, 2026

Sep 18, 2026

Is Arrowhead Pharmaceuticals (ARWR) A Bargain On Strong ARO DIMER PA Trial Data? - simplywall.st

Sep 18, 2026

Sep 17, 2026

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Envista Holdings (NVST) - The Globe and Mail

Sep 17, 2026

Sep 16, 2026

Arrowhead Pharmaceuticals Plans Supplemental Drug Approval Application - Intellectia AI

Sep 16, 2026

Sep 16, 2026

Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’ - Yahoo Finance

Sep 16, 2026

Sep 16, 2026

Arrowhead Pharmaceuticals, Inc. rStock (RARWR) Price Prediction for 2026 to 2031 - Bybit

Sep 16, 2026

Sep 16, 2026

Arrowhead Achieves Clinical Validation for New Drug Platform - Benzinga

Sep 16, 2026

Sep 15, 2026

Arrowhead Tackles Two Targets To Lower Multiple ASCVD-Causing Lipids - insights.citeline.com

Sep 15, 2026

Sep 15, 2026

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move? - Yahoo Finance

Sep 15, 2026

Sep 15, 2026

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know - TradingKey

Sep 15, 2026

Sep 15, 2026

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Yahoo Finance

Sep 15, 2026

Sep 10, 2026

How Investors May Respond To Arrowhead Stock Phase 3 Trial Results - webull.com

Sep 10, 2026

Sep 09, 2026

Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily

Sep 09, 2026

Sep 09, 2026

ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus

Sep 09, 2026

Sep 08, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News & Headlines - finance.yahoo.com

Sep 08, 2026

Sep 08, 2026

ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus

Sep 08, 2026

Sep 08, 2026

ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance

Sep 08, 2026

Sep 08, 2026

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target - Yahoo Finance

Sep 08, 2026

Sep 06, 2026

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance

Sep 06, 2026

Sep 04, 2026

Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance

Sep 04, 2026

Sep 03, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.

Sep 03, 2026

Sep 02, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha

Sep 02, 2026

Sep 01, 2026

ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus

Sep 01, 2026

Sep 01, 2026

Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance

Sep 01, 2026

Aug 31, 2026

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com

Aug 31, 2026

Aug 31, 2026

Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance

Aug 31, 2026

Aug 31, 2026

Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com

Aug 31, 2026